Haematopoietic stem cell transplantation for poor-prognosis systemic sclerosis

Rheumatology (United Kingdom)

Volumn 54, Issue 12, 2015, Pages 2126-2133

  van Laar, Jacob M ^a   Naraghi, Kamran ^b   Tyndall, Alan ^c  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^b UNIVERSITY OF LEEDS   (United Kingdom)

^c UNIVERSITY HOSPITAL BASEL   (Switzerland)

Author keywords

Haematopoietic stem cell transplantation; Remission induction; Systemic sclerosis

Indexed keywords

AUTOANTIBODY; IMMUNOSUPPRESSIVE AGENT;

ARTICLE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; MORTALITY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROGNOSIS; RANDOMIZED CONTROLLED TRIAL (TOPIC); RELAPSE; SYSTEMIC SCLEROSIS;

EID: 84983134063     PISSN: 14620324     EISSN: 14620332     Source Type: Journal    
DOI: 10.1093/rheumatology/kev117     Document Type: Article

References (43)

1. Tamm M, Gratwohl A, Tichelli A, Perruchoud AP, Tyndall A. Autologous haemopoietic stem cell transplantation in a patient with severe pulmonary hypertension complicating connective tissue disease. Ann Rheum Dis 1996;55:779-80.
2. Tyndall A, Black C, Finke J et al. Treatment of systemic sclerosis with autologous haemopoietic stem cell transplantation. Lancet 1997;349:254.
3. Tyndall A, Fassas A, Passweg J et al. Autologous haematopoietic stem cell transplants for autoimmune disease-feasibility and transplant-related mortality. Autoimmune Disease and Lymphoma Working Parties of the European Group for Blood and Marrow Transplantation, the European League Against Rheumatism and the International Stem Cell Project for Autoimmune Disease. Bone Marrow Transpl 1999;24: 729-34.
4. Steen VD, Medsger TA Jr. Long-term outcomes of scleroderma renal crisis. Ann Intern Med 2000;133:600-3.
5. Rubenfire M, Huffman MD, Krishnan S et al. Survival in systemic sclerosis with pulmonary arterial hypertension has not improved in the modern era. Chest 2013;144: 1282-90.
6. Chung L, Domsic RT, Lingala B et al. Survival and predictors of mortality in systemic sclerosis-associated pulmonary arterial hypertension: outcomes from the pulmonary hypertension assessment and recognition of outcomes in scleroderma registry. Arthritis Care Res 2014; 66:489-95.
7. Binks M, Passweg JR, Furst D et al. Phase I/II trial of autologous stem cell transplantation in systemic sclerosis: procedure related mortality and impact on skin disease. Ann Rheum Dis 2001;60:577-84.
8. Feghali-Bostwick C, Medsger TA Jr, Wright TM. Analysis of systemic sclerosis in twins reveals low concordance for disease and high concordance for the presence of antinuclear antibodies. Arthritis Rheum 2003;48: 1956-63.
9. McKendry RJ, Huebsch L, Leclair B. Progression of rheumatoid arthritis following bone marrow transplantation. A case report with a 13-year followup. Arthritis Rheum 1996;39:1246-53.
10. Nash RA, McSweeney PA, Nelson JL et al. Allogeneic marrow transplantation in patients with severe systemic sclerosis: resolution of dermal fibrosis. Arthritis Rheum 2006;54:1982-6.
11. Daikeler T, Hügle T, Farge D et al. Allogeneic hematopoietic SCT for patients with autoimmune diseases. Bone Marrow Transpl 2009;44:27-33.
12. Knaan-Shanzer S, Houben P, Kinwel-Bohre EP, van Bekkum DW. Remission induction of adjuvant arthritis in rats by total body irradiation and autologous bone marrow transplantation. Bone Marrow Transpl 1991;8:333-8.
13. Gratwohl A, Passweg J, Bocelli-Tyndall C et al. Autologous hematopoietic stem cell transplantation for autoimmune diseases. Bone Marrow Transpl 2005;35: 869-79.
14. Snowden JA, Saccardi R, Allez M et al. Haematopoietic SCT in severe autoimmune diseases: updated guidelines of the European Group for Blood and Marrow Transplantation. Bone Marrow Transpl 2012;47:770-90.
15. van Laar JM, Sullivan K. Stem cell transplantation in systemic sclerosis. Curr Opin Rheumatol 2013;25:719-25.
16. Nash RA, McSweeney PA, Crofford LJ et al. High-dose immunosuppressive therapy and autologous hematopoietic cell transplantation for severe systemic sclerosis: long-term follow-up of the US multicenter pilot study. Blood 2007;110:1388-96.
17. Henes JC, Schmalzing M, Vogel W et al. Optimization of autologous stem cell transplantation for systemic sclerosis- a single-center longterm experience in 26 patients with severe organ manifestations. J Rheumatol 2012;39: 269-75.
18. van Laar JM, Farge D, Sont JK et al. Autologous hematopoietic stem cell transplantation versus intravenous pulse cyclophosphamide in diffuse cutaneous systemic sclerosis: a randomized clinical trial. JAMA 2014;311: 2490-8.
19. Farge D, Marolleau JP, Zohar S et al. Autologous bone marrow transplantation in the treatment of refractory systemic sclerosis: early results from a French multicentre phase I-II study. Br J Haematol 2002;119:726-39.
20. Burt RK, Oliveira MC, Shah SJ et al. Cardiac involvement and treatment-related mortality after non-myeloablative haemopoietic stem-cell transplantation with unselected autologous peripheral blood for patients with systemic sclerosis: a retrospective analysis. Lancet 2013;381: 1116-24.
21. Farge D, Labopin M, Tyndall A et al. Autologous hematopoietic stem cell transplantation for autoimmune diseases: an observational study on 12 years' experience from the European Group for Blood and Marrow Transplantation Working Party on Autoimmune Diseases. Haematologica 2010;95:284-92.
22. Bassler D, Briel M, Montori VM et al. Stopping randomized trials early for benefit and estimation of treatment effects: systematic review and meta-regression analysis. JAMA 2010;303:1180-7.
23. Smith V, Piette Y, van Praet JT et al. Two-year results of an open pilot study of a 2-treatment course with rituximab in patients with early systemic sclerosis with diffuse skin involvement. J Rheumatol 2013;40:52-7.
24. Khanna D, Distler O, Avouac J et al. Measures of response in clinical trials of systemic sclerosis: the Combined Response Index for Systemic Sclerosis (CRISS) and Outcome Measures in Pulmonary Arterial Hypertension related to Systemic Sclerosis (EPOSS). J Rheumatol 2009; 36:2356-61.
25. Hudson M, Steele R, Baron M. Update on indices of disease activity in systemic sclerosis. Semin Arthritis Rheum 2007;37:93-8.
26. Steen VD, Medsger TA Jr. Improvement in skin thickening in systemic sclerosis associated with improved survival. Arthritis Rheum 2001;44:2828-35.
27. Farge D, Passweg J, van Laar JM et al. Autologous stem cell transplantation in the treatment of systemic sclerosis: report from the EBMT/EULAR Registry. Ann Rheum Dis 2004;63:974-81.
28. Henes JC, Koetter I, Horger M et al. Autologous stem cell transplantation with thiotepa-based conditioning in patients with systemic sclerosis and cardiac manifestations. Rheumatology 2014;53:919-22.
29. Burt RK, Oyama Y, Traynor A et al. Hematopoietic stem cell transplantation for systemic sclerosis with rapid improvement in skin scores: is neoangiogenesis occurring? Bone Marrow Transpl 2003;32(Suppl 1): S65-7.
30. Verrecchia F, Laboureau J, Verola O et al. Skin involvement in scleroderma-where histological and clinical scores meet. Rheumatology 2007;46:833-41.
31. Fleming JN, Nash RA, McLeod DO et al. Capillary regeneration in scleroderma: stem cell therapy reverses phenotype? PLoS One 2008;3:e1452.
32. Aschwanden M, Daikeler T, Jaeger KA et al. Rapid improvement of nailfold capillaroscopy after intense immunosuppression for systemic sclerosis and mixed connective tissue disease. Ann Rheum Dis 2008;67: 1057-9.
33. Hügle T, van Laar JM. Stem cell transplantation for rheumatic autoimmune diseases. Arthritis Res Ther 2008; 10:217.
34. Burt RK, Shah SJ, Dill K et al. Autologous non-myeloablative haemopoietic stem-cell transplantation compared with pulse cyclophosphamide once per month for systemic sclerosis (ASSIST): an open-label, randomised phase 2 trial. Lancet 2011;378:498-506.
35. Lee DW, Gardner R, Porter DL et al. Current concepts in the diagnosis and management of cytokine release syndrome. Blood 2014;124:188-95.
36. Ehlers SL, Gastineau DA, Patten CA et al. The impact of smoking on outcomes among patients undergoing hematopoietic stem cell transplant for the treatment of acute leukemia. Bone Marrow Transpl 2011;46:285-90.
37. Hung EW, Mayes MD, Sharif R et al. Gastric antral vascular ectasia and its clinical correlates in patients with early diffuse systemic sclerosis in the SCOT trial. J Rheumatol 2013;40:455-60.
38. Daikeler T, Labopin M, Di Gioia M et al. Secondary autoimmune diseases occurring after HSCT for an autoimmune disease: a retrospective study of the EBMT Autoimmune Disease Working Party. Blood 2011;118: 1693-8.
39. Jordan S, Distler JH, Maurer B et al. Effects and safety of rituximab in systemic sclerosis: an analysis from the European Scleroderma Trial and Research (EUSTAR) group. Ann Rheum Dis 2014 Jan 17, doi: 10.1136/ annrheumdis-2013- 204522 [Epub ahead of print].
40. Saccardi R, Tyndall A, Coghlan G et al. Consensus statement concerning cardiotoxicity occurring during haematopoietic stem cell transplantation in the treatment of autoimmune diseases, with special reference to systemic sclerosis and multiple sclerosis. Bone Marrow Transpl 2004;34:877-81.
41. Hudson M, Baron M, Tatibouet S et al. Exposure to ACE inhibitors prior to the onset of scleroderma renal crisis- results from the International Scleroderma Renal Crisis Survey. Semin Arthritis Rheum 2014;43:666-72.
42. Fransen J, Popa-Diaconu D, Hesselstrand R et al. Clinical prediction of 5-year survival in systemic sclerosis: validation of a simple prognostic model in EUSTAR centres. Ann Rheum Dis 2011;70:1788-92.
43. Domsic RT, Rodriguez-Reyna T, Lucas M, Fertig N, Medsger TA Jr. Skin thickness progression rate: a predictor of mortality and early internal organ involvement in diffuse scleroderma. Ann Rheum Dis 2011;70:104-9, correction 2011;70:1350.